Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

MELBOURNE, Australia and BOLOGNA, Italy, Sept. 13, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Bologna-based RADIUS S.r.l. (Radius) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 […] Lire la suite »

Samsung Bioepis Announces Five-year Follow-up Results for ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2 Positive Breast Cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

Five-year follow-up results show comparable cardiac safety profile and long-term efficacy between biosimilar ONTRUZANT® (trastuzumab) and reference medicine HERCEPTIN® i (trastuzumab) in early or locally advanced HER2 positive breast cancer The longest monitoring data of patients treated with a trastuzumab biosimilar for HER2-positive early or locally advanced breast cancer Results […] Lire la suite »